PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.26%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.40%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
13.78%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.03%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
60.88%
EBIT growth of 60.88% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
78.82%
Operating income growth of 78.82% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
59.23%
Net income growth of 59.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
55.38%
EPS growth of 55.38% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
55.38%
Diluted EPS growth of 55.38% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
385.68%
OCF growth exceeding 1.5x Medical - Pharmaceuticals median of 2.05%. Joel Greenblatt would see if a superior business model or cost structure drives strong cash generation.
294.03%
FCF growth exceeding 1.5x Medical - Pharmaceuticals median of 0.73%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
10.87%
10Y CAGR of 10.87% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
10.87%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 6.38%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
10.87%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 5.78%. Joel Greenblatt might see a short-term competitive advantage at play.
20.32%
OCF/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 2.67% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
20.32%
OCF/share CAGR of 20.32% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
20.32%
3Y OCF/share growth of 20.32% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
23.37%
Net income/share CAGR 50-75% of Medical - Pharmaceuticals median. Guy Spier would see lagging competitiveness in core profitability.
23.37%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.34%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
23.37%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.19%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
22.09%
Equity/share CAGR of 22.09% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
22.09%
5Y equity/share CAGR of 22.09% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
22.09%
3Y equity/share CAGR of 22.09% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
-61.67%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-61.67%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
-61.67%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
No Data
No Data available this quarter, please select a different quarter.
-0.54%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
10.14%
Asset growth of 10.14% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
6.28%
BV/share growth of 6.28% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
11.04%
Debt growth of 11.04% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.